Biotech Values

[DewDiligence]

Good article. Yes, there are lots of questions but, overall, these phase-2 data can’t be awful or the companies would not have embarked on a very expensive phase-3 program. (As stated in a prior post, Zebra’s Law does not apply nearly as strongly to Big Pharma as it does to small biotech companies.) Regards, Dew